ClinicalTrials.gov
public full text
Public Domain
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.#869068
- Atamparib in Patients With Advanced Solid Tumors#1173590
- Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy#1294572
- One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab#1293479
- Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)#1111374
Record · ID 1363452
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive